Compritol®-based solid lipid nanoparticles of desvenlafaxine prepared by ultrasonication-assisted hot-melt encapsulation to modify its release.
Nanomedicine (Lond)
; 19(11): 965-978, 2024.
Article
in En
| MEDLINE
| ID: mdl-38593058
ABSTRACT
Aims:
Desvenlafaxine (DES) in conventional dosage forms shows initial burst release after oral administration, leading to exaggeration of its side effects. These side effects can be overcome by a sustained-release dosage form using the chemically inert, low-melting-point lipid Compritol® 888 ATO, as it reduces initial burst release. Materials &methods:
The potential of DES-loaded solid lipid nanoparticles (DES-SLNs) synthesized by ultrasonication-assisted hot-melt encapsulation to modify the release of DES was investigated.Results:
The entrapment efficiency of DES-SLNs was 65.90% with the in vitro release profile showing a sustained-release behavior achieving 81% cumulative release within 16 h without initial burst release.Conclusion:
DES-SLNs are a potential carrier for sustained release of water-soluble antidepressant drugs such as DES.
[Box see text].
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Delayed-Action Preparations
/
Nanoparticles
/
Drug Liberation
/
Desvenlafaxine Succinate
Limits:
Humans
Language:
En
Journal:
Nanomedicine (Lond)
Year:
2024
Document type:
Article
Affiliation country:
Pakistan